Sun Pharma gets USFDA approval for Alopecia treatment drug

The drug is likely to see potential sales worth $200 million in the next three to four years and will add to Sun Pharma's specialty portfolio.

India's largest drugmaker Sun Pharmaceuticals Ltd. informed the exchanges that it has received the United States Food and Drug Administration (USFDA) approval for a New Drug Application (NDA) called Deuruxolitinib, which is used in the treatment of Alopecia Areata.

The drug has been branded as LEQSELVI and will be in the form of 8 mg tablets, used in the treatment of adults.

Sun Pharma said that the LEQSELVI approval is based on data from two multi-centre double blind placebo controlled phase 3 trials, which had around 1,220 patients enrolled.

The US Drug regulator had approved the filing acceptance of the NDA for Deuruxolitinib.

“LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians,” said Abhay Gandhi, CEO, North America Business, Sun Pharma. “Our fast-growing dermatology business is excited to add this novel treatment to its portfolio,” he added.

Alopecia areata is a common autoimmune disease in which hair loss is thought to occur due to the collapse of immune privilege, leading to the immune system targeting the hair follicles and causing sudden hair loss on the scalp, face and sometimes other areas of the body.

The drug is likely to see potential sales worth $200 million in the next three to four years and will add to Sun Pharma's specialty portfolio.

Sun Pharma's shares ended 2.4% higher on Thursday at ₹1,657.65. The stock has risen 31% so far in 2024.

News Source:

https://www.cnbctv18.com/market/sun-pharma-share-price-usfda-approval-alopecia-treatment-drug-average-sales-trials-19449424.htm